Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.62 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | KIT | P10721 | 5/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | ULK1 | O75385 | 6/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 2/20 | 0.37 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15020468 | 0.91 | ORAI1 (0.59) | ORAI1ABL1KITBRD4ULK1 | |
| SCHEMBL15036305 | 0.87 | ORAI1 (0.55) | ORAI1KITULK1FGFR2FGFR3 | |
| SCHEMBL15751300 | 0.83 | ORAI1 (0.86) | ORAI1ABL1BRD4ULK1FGFR2 | |
| SCHEMBL15020464 | 0.81 | ORAI1 (0.59) | ORAI1ABL1ULK1FGFR2FGFR3 | |
| SCHEMBL18944203 | 0.78 | ORAI1 (0.47) | ORAI1ULK1 | |
| SCHEMBL15750813 | 0.76 | ORAI1 (1.00) | ORAI1ABL1BRD4ULK1FGFR2 | |
| SCHEMBL15020509 | 0.76 | ORAI1 (0.72) | ORAI1KITBRD4ULK1 | |
| SCHEMBL15751097 | 0.76 | ORAI1 (0.74) | ORAI1ABL1BRD4ULK1FGFR2 | |
| SCHEMBL15020550 | 0.76 | ORAI1 (0.53) | ORAI1BRD4ULK1FGFR2FGFR3 | |
| SCHEMBL1459919 | 0.72 | ORAI1 (0.54) | ORAI1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158049-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | claimed |
| WO-2013092467-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| US-20130158049-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158049-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | ORAI1, CACNA1I, RYR2 | ORAI1 1/4885ABL1 2631/4885KIT 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.